However, this contrasts with the promising intracranial results observed in the HERTHENA-Lung01 trial using HER3-DXd in EGFR-mutant NSCLC, where HER3 is unlikely to act as the primary oncogenic driver. This evidence concerns the gene EGFR and non-small cell lung carcinoma.